AVE1642 + erlotinib

**AVE1642 + erlotinib** is an investigational combination therapy consisting of the humanized monoclonal antibody **AVE1642**, which targets the *type 1 insulin-like growth factor receptor (IGF-1R)*, and **erlotinib**, a small molecule tyrosine kinase inhibitor of *epidermal growth factor receptor (EGFR)*. AVE1642 selectively binds IGF-1R, blocking its activation and downstream signaling, resulting in inhibition of cancer cell survival, growth, and resistance mechanisms[1][2][3]. Erlotinib inhibits EGFR tyrosine kinase, preventing cell proliferation and promoting apoptosis. This combination has been evaluated in phase I clinical studies for advanced solid tumors, aiming to overcome resistance associated with IGF-1R and EGFR pathways.

Other names

AVE1642AVE-1642AVE 1642erlotinib